Biochemical Parameters in Obese Egyptian Patients as a Non-Invasive Marker for Disease Screening in Early Diagnosis of Non-Alcoholic Fatty Liver Disease
DOI:
https://doi.org/10.3889/oamjms.2020.4001Keywords:
Obesity, Non-alcoholic fatty liver disease, Biochemical parametersAbstract
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) has recently been considered as the most public liver problem worldwide and a major clinicopathologic health burden in the developed countries. Biochemical tests are important in verifying a better understanding of many diseases and hence help to have the right decisions for achieving better management.
AIM: This study was conducted to assess biochemical markers in NAFLD Egyptian patients.
METHODS: Forty obese subjects (32 females and 8 males, mean age was 42.32 ± 9.12 years) (20 with NAFLD and 20 without NAFLD) and 20 normal participants were selected.
RESULTS: Body mass index (BMI) was 40.86 ± 5.45 in obese FL versus 22.07 ± 2.10 in control, p < 0.001 and versus 35.83 ± 5.94 in obese non-FL, p = 0.003. Alanine aminotransferase (ALT) was 57.30 ± 46.24 in obese FL versus 25.45 ± 7.12 in control, p = 0.003 and versus 27.35 ± 11.09 in obese non-FL, p = 0.005. Aspartate aminotransferase (AST) (41.40 ± 36.09 in obese FL vs. 21.7 ± 3.81 in control, p = 0.015 and vs. 24.05 ± 7.50 in obese non-FL, p = 0.032). Total bilirubin (T.Bil) (0.62 ± 0.25 in obese FL vs. 0.47 ± 0.15 in control, p = 0.014). Prothrombin time (PT) (86.80 ± 11.32 in obese FL vs. 97.86 ± 4.31 in control, p < 0.001) and International Normalization Ratio (INR) (1.11 ± 0.13 in obese FL vs. 1.01 ± 0.02 in control, p = 0.002). Triglycerides (TGs) (128.20 ± 43.49 in obese FL vs. 88.35 ± 24.26 in control, p < 0.001 and vs. 94.50 ± 31.65 in obese non-FL, p = 0.003). Ferritin (88.21 ± 54.88 in obese FL vs. 47.65 ± 32.07 in obese non-FL, p = 0.006). Alpha-fetoprotein (AFP) (2.42 ± 1.67 in obese FL vs. 1.20 ± 0.75 in control, p = 0.001). Fasting blood sugar (FBS) (119.70 ± 49.11 in obese FL vs. 84.10 ± 7.19 in control, p < 0.001 and vs. 80.50 ± 8.84 in obese non-FL, p < 0.001) and postprandial (P.P) (152.80 ± 82.86 in obese FL vs. 94.35 ± 3.70 in control, p < 0.001 and vs. 93.35 ± 7.77 in obese non-FL, p < 0.001). Serum high-density lipoprotein (HDL) level was significantly lower in NAFLD patients compared to obese non-FL (40.05 ± 5.81 vs. 41.9 ± 4.85, p < 0.001).
CONCLUSION: NAFLD is associated with changes in biochemical parameters. Its early assessment can help in modifying the disease course and delaying complications.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Yang M, Zhang Y, Ren J. Autophagic Regulation of Lipid Homeostasis in Cardiometabolic Syndrome. Front. Cardiovasc. Med., 2018; 5(38). https://doi.org/10.3389/fcvm.2018.00038
Barros F, Setúbal S, Martinho JJ, Ferraz L, Gaudêncio A. Correlation of non-alcoholic fatty liver disease and features of metabolic syndrome in morbidly obese patients in the preoperative assessment for bariatric surgery. ABCD Arq Bras Cir Dig. 2016;29(4):260-3. https://doi. org/10.1590/0102-6720201600040011 PMid:28076482
Alebshehy R, Shuaib NM, Mbako JD, Barffo D, Nuotol RK. Determinant analysis of obesity among adult females in Egypt. Egypt J Hosp Med. 2016;65:662-9. https://doi. org/10.12816/0033779
Host KW, Serlie MJ. Fructose consumption, lipogenesis, and non-alcoholic fatty liver disease. Nutrients. 2017;9(9):981. https://doi.org/10.3390/nu9090981 PMid:28878197
Mikolasevic I, Filipec-Kanizaj T, Mijic M, Jakopcic I, Milic S, Hrstic I, et al. Nonalcoholic fatty liver disease and liver transplantation where do we stand? World J Gastroenterol. 2018;24(14):1491-506. https://doi.org/10.3748/wjg.v24.i14.1491 PMid:29662288
Masarone M, Rosato V, Dallio M, Gravina AG, Aglitti A, Loguercio C, et al. Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease. Oxid Med Cell Longev. 2018;2018:9547613. https://doi.org/10.1155/2018/9547613 PMid:29991976
Cho JH, Namgung JS, Lee J, Moon DH, Lee HK. Analysis of biochemical markers related to fatty liver patients. J Phys Ther Sci. 2014;26(12):1865-8. https://doi.org/10.1589/jpts.26.1865 PMid:25540483
Lee DH. Imaging evaluation of non-alcoholic fatty liver disease: Focused on quantification. Clin Mol Hepatol. 2017;23(4):290- 301. https://doi.org/10.3350/cmh.2017.0042 PMid:28994271
Maharjan P, Khanal P, Parajuli NP, Joshi G, Parajuli H, Khanal S, et al. Biochemical changes in non-alcoholic fatty liver disease (NAFLD): A study in Nepalese population ACCLM. 2016;2(2):15-20. https://doi.org/10.3126/acclm.v2i2.15597
Doumas BT, Kwok-Cheung PP, Perry BW, Jendrzejczak B, McComb RB, Schaffer R, et al. Candidate reference method for determination of total bilirubin in serum: Development and validation. Clin Chem. 1985;31(11):1779-89. https://doi. org/10.1093/clinchem/31.11.1779 PMid:4053346
Doumas BT, Perry BW, Sasse EA, Straumjord JV. Standardization in bilirubin assays: Evaluations of selected methods and stability of bilirubin solutions. Clin Chem; 19:984- 993. https://doi.org/10.1093/clinchem/19.9.984
Bergmeyer HU, Scheibe P, Wahlefeld AW. Optimization of methods for aspartate aminotransferase and alanine aminotransferase. Clin Chem 1978;24(1):58-73. https://doi. org/10.1093/clinchem/24.1.58 PMid:22409
Saris NE. Revised IFCC method for aspartate aminotransferase. Clin Chem. 1978;24:720-1.
Bowers GN, McComb RB. A continuous spectrophtometric method for measuring the activity of serum alkaline phosphatase. Clin Chem. 1966;12(2):70-89. https://doi.org/10.1093/ clinchem/12.2.70 PMid:4952423
Henry RJ, Sobel C, Berkman S. Interferences with biuret methods for serum proteins. Anal Chem. 1957;29(10):1491-5. https://doi.org/10.1021/ac60130a028
Louderback A, Mealey EH, Taylor NA. A new dye-binder technic using bromocresol purple for determination of albumin in serum. Clin Chem. 1968;14:793-4.
Shaw LM, Stromme JH, London JL, Theodorsen L. International federation of clinical chemistry, (IFCC), scientific committee, analytical section. IFCC methods for the measurement of catalytic concentration of enzymes. Part 4. IFCC method for gamma-glutamyltransferase [(gamma-glutamyl)-peptide: amino acid gamma-glutamyltransferase, EC 2.3.2.2]. J Clin Chem Clin Biochem. 1983;21(10):633-46. https://doi.org/10.1155/ s1463924690000049
Kunst A, Draeger B, Ziegenhorn J. UV-methods with hexokinase and glucose-6-phosphate dehydrogenase. Methods Enzym Anal. 1983;23:163-72.
Van der Poel CL, Cuypers HT, Reesink HW, Weiner AJ, Quan S, Di Nello R, et al. Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay. Lancet. 1991;337(8737):317-9. https://doi. org/10.1016/0270-9139(91)90067-6 PMid:1671231
Thomas L, editor. Clinical Laboratory Diagnostics. Germany: Th-Books Verlagsgesellschaft mbH, Frankfurt/Main; 1998. p. 1263-73.
Tan EM, Smolen JS, McDougal JS, Butcher BT, Conn D, Dawkins R. A critical evaluation of enzyme immunoassays for the detection of antinuclear antibody of defined species. Arthritis Rheum. 1999;42(3):455-64. PMid:10088768
Uotila M, Ruoslahti E, Engvall E. Two-site sandwich enzyme immunoassay with monoclonal antibodies to human alphafetoprotein. J Immunol Methods. 1981;42:11-5. https://doi. org/10.1016/0022-1759(81)90219-2 PMid:6165775
Miravitlles M, Herr C, Ferrarotti I, Jardi R, Rodriguez-Frias F, Luisetti F, et al. Laboratory testing of individuals with severe a1-antitrypsin deficiency in three European centres. Eur Respir J. 2010;35(5):960-8. https://doi.org/10.1183/09031936.00069709 PMid:20436173
White D, Kramer D, Johnson G, Dick F, Hamilton H. Estimation of serum ferritin by using enzyme immunoassay method. Am J Clin Pathol. 1986;72:346-51.
Kroll CA, Ferber MJ, Dawson BD, Jacobson RM, Mensink KA, Lorey F, et al. Retrospective determination of ceruloplasmin in newborn screening blood spots of patients with Wilson disease. Mol Genet Metab. 2006;89(1-2):134-8. https://doi.org/10.1016/j. ymgme.2006.03.008 PMid:16644258
Rautela GS, Liedtke RJ. Automated measurement of total cholesterol in serum. Clin Chem. 1978;24(1):108-14. https://doi. org/10.1093/clinchem/24.1.108 PMid:618640
Rautela GS, Hall RG, Bekiesz CL, Wermus GR. A kinetic method for rapid and automatic measurement of triglycrieds in biological fluids. Clin Chem. 1974;20:857.
Moshides JS. Kinetic enzymatic method for automated determination of HDL cholesterol in plasma. Clin Chem Biochem. 1987;25(9):583-7. https://doi.org/10.1515/cclm.1987.25.9.583 PMid:3681196
Taussky HH. Creatinine and creatine in urine and serum. In: Seligson S, editor. Standard Methods of Clinical Chemistry. Vol. 3. New York: Academic Press; 1961. p. 99. https://doi. org/10.1016/b978-1-4831-9684-8.50015-6
Talke H, Schubert GE. Enzymatische harnstoffbestimmung in blut und serum in optischen test nach Warburg. J Mol Med. 1965;43(3):174-5. https://doi.org/10.1007/bf01484513
Henry JB, editor. Clinical Diagnosis and Management by Laboratory Methods. 18th ed. Philadelphia, PA: WB Saunders; 1991.
Zhanga J, Abbasib O, Malevanchikc L, Mohana N, Denicolaa R, Tarangeloa N, et al. Pilot study of the prevalence of binge eating disorder in non-alcoholic fatty liver disease patients. Ann Gastroenterol. 2017;30:664-9. https://doi.org/10.20524/ aog.2017.0200 PMid:29118561
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67(1):328-57. https://doi.org/10.1002/hep.29367 PMid:28714183
Yang C, Yang S, Xu W, Zhang J, Fu W, Feng C. Association between the hyperuricemia and nonalcoholic fatty liver disease risk in a Chinese population: A retrospective cohort study. PLoS One. 2017;12(5):e0177249. https://doi.org/10.1371/journal. pone.0177249 PMid:28510581
Alam S, Mustafa G, Alam M, Ahmad N. Insulin resistance in development and progression of nonalcoholic fatty liver disease. World J Gastrointest Pathophysiol. 2016;7(2):211-7. https://doi. org/10.4291/wjgp.v7.i2.211 PMid:27190693
Kumar R, Mohan S. Non-alcoholic fatty liver disease in lean subjects: Characteristics and implications. J Clin Transl Hepatol. 2017;5:216-23. PMid:28936403
Bertot LC, Adams LA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci. 2016;17(5):774-86. https://doi. org/10.3390/ijms17050774
Fracanzani AL, Valenti L, Bugianesi E, Vanni E, Grieco A, Miele L, et al. Risk of nonalcoholic steatohepatitis and fibrosis in patient with nonalcoholic fatty liver disease and low visceral adiposity. J Hepatol. 2011;54(6):1244-9. https://doi. org/10.1016/j.jhep.2010.09.037 PMid:21145841
Zawdie B, Tadesse S, Wolide AD, Nigatu TA, Bobasa EM. Non-alcoholic fatty liver disease and associated factors among Type 2 diabetic patients in Southwest Ethiopia. Ethiop J Health Sci. 2018;28(1):19. https://doi.org/10.4314/ejhs.v28i1.4 PMid:29622904
Zaki M, Yousef W, Kamal S, Mohamed R, Saleh O, Ezzat W. Association between metabolic abnormalities and non-alcoholic fatty liver in obese premenopausal women. Biomed Pharmacol J. 2018;11(2):1161-6. https://doi.org/10.13005/ bpj/1477
López-Amador N, Nolasco-Hipolito C, Rojas-Jimeno MJ, Carvajal-Zarrabal O. Liver enzymes in patients diagnosed with non-alcoholic fatty liver disease (NAFLD) in Veracruz: A comparative analysis with the literature. Clin Invest (Lond.) 2017;7(1):25-32. https://doi.org/10.4172/ clinical-investigation.1000107
Rasool A, Dar W, Latief M, Dar I, Sofi N, Khan MA. Nonalcoholic fatty liver disease as an independent risk factor for carotid atherosclerosis. Brain Circ. 2017;3:235.
Hadizadeh F, Faghihimani E, Adibi P. Nonalcoholic fatty liver disease: Diagnostic biomarkers. World J Gastrointest Pathophysiol. 2017;8(2):11-26. https://doi.org/10.4291/wjgp. v8.i2.11 PMid:28573064
Anwar MS, Dillon JF, Miller MH. Association of serum bilirubin and non-alcoholic fatty liver disease: A feasible therapeutic avenue? World J Pharmacol. 2014;3(4):209-16. https://doi. org/10.5497/wjp.v3.i4.209
Tian J, Zhong R, Liu C, Tang Y, Gong J, Chang J, et al. Association between bilirubin and risk of Non-Alcoholic Fatty Liver Disease based on a prospective cohort study. Sci Rep. 2016;6:31006.
Saremi Z, Rastgoo M, Mohammadifard M, Bijari B, Akbari E. Comparison of platelet number and function between nonalcoholic fatty liver disease and normal individuals. J Res Med Sci. 2017;22:75. https://doi.org/10.4103/jrms.jrms_711_16 PMid:28717372
Macherla R. Clinical study of non-alcoholic fatty liver disease in patients with Type 2 diabetes mellitus. Asian Pac J Health Sci. 2017;3(4):176-83. https://doi.org/10.21276/apjhs.2016.3.4.28
Saini MS, Khurana P, Arora U. Variations in fasting blood sugar and glycosylated hemoglobin levels in fatty liver in north west punjabi population. Int J Recent Sci Res. 2015;6(6):4629-32.
Pang Y, Kartsonaki C, Turnbull I, Guo Y, Clarke R, Chen Y, et al. Diabetes, plasma glucose, and incidence of fatty liver, cirrhosis, and liver cancer: A prospective study of 0.5 million people. Hepatology. 2018;68(4):4. https://doi.org/10.1002/hep.30083 PMid:29734463
Gitto S, Schepis F, Andreone P, Villa E. Study of the serum metabolomic profile in nonalcoholic fatty liver disease: Research and clinical perspectives. Metabolites. 2018;8(1):17. https://doi. org/10.3390/metabo8010017
Cang Z, Wang N, Li Q, Han B, Chen Y, Zhu C, et al. Study of the cut-off level of ALT and TG to predict the risk of nonalcoholic fatty liver disease in Eastern China. Int J Clin Exp Med. 2017;10(5):8223-9.
Darmawan G, Hamijoyo L, Hasan I. Association between serum uric acid and non-alcoholic fatty liver disease: A Meta-Analysis. Acta Med Indones. 2017;49(2):136-47. PMid:28790228
Feng RN, Du SS, Wang C, Li YC, Liu LY, Guo FC, et al. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population. World J Gastroenterol. 2014;20(47):17932-40. https://doi.org/10.3748/ wjg.v20.i47.17932 PMid:25548491
Babali A, Çakal E, Purnak T, Biyikoğlu I, Çakal B, Yüksel O, et al. Serum a-fetoprotein levels in liver steatosis. Hepatol Int. 2018;3(4):551-5. https://doi.org/10.1007/s12072-009-9156-8 PMid:19890679
Xu P, Xu CF, Wan XY, Yu CH, Shen C, Chen P, et al. Association between serum alpha-fetoprotein levels and fatty liver disease: A cross-sectional study. World J Gastroenterol. 2014;20(33):11865-70. https://doi.org/10.3748/wjg.v20.i33.11865 PMid:25206293
Xu R, Jiang YF, Zhang YH, Yang X. The optimal threshold of serum ceruloplasmin in the diagnosis of Wilson’s disease: A large hospital-based study. PLoS One. 2018;13(1):e0190887. https://doi.org/10.1371/journal.pone.0190887
PMid:29324775
Du SX, Lu LL, Geng N, Victor D, Chen LZ, Wang C, et al. Association of serum ferritin with nonalcoholic fatty liver disease: A meta-analysis. Lipids Health Dis. 2017;16(1):228. https://doi. org/10.1186/s12944-017-0613-4
PMid:29197393
Barros RK, Cotrim HP, Daltro CH, Oliveira YA. Hyperferritinemia in patients with nonalcoholic fatty liver disease. Rev Assoc Med Bras. 2017;63(3):284-9. https://doi. org/10.1590/1806-9282.63.03.284 PMid:28489136
Downloads
Published
How to Cite
License
Copyright (c) 2020 Wafaa Ghoneim Shousha, Yasser I. El Nahass, Marwa K. Darwish, Assmaa H. Mahmoud, Sherif Mogawer (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
